Abstract 1059P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under pathological conditions. However, the clinical implications of localization and maturation stage of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
Immunohistochemistry and multispectral fluorescent were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic and immunological implications of the TLS heterogeneity in 625 patients with ccRCC from multiply cohorts. Associations between TLS heterogeneity and immunologic activities were assessed by the quantification of immune cells infiltration.
Results
TLS typically comprises B-cell follicles with germinal centers and are surrounded by T-cell zones and dendritic cells. TLS infiltrates were identified in 34.2% of the ccRCC samples. A higher proportion of early TLS was found in peritumoral TLS, while intratumoral TLS mainly comprised secondary follicle-like. Kaplan-Meier analyses indicated that the presence of intratumoral TLS markedly correlated with both superior progression-free survival PFS and OS, while the presence of peritumoral TLS showed the opposite predictive trends for outcomes. Notably, presence of TLS, especially intratumoral TLS and mature TLS (namely SFL-TLS, with CD23+ germinal center) significantly correlated with better clinical outcomes and objective reflection rate for ccRCC patients receiving immunotherapies. Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the peritumoral regions increased prominently, showing a typical suppressive TME characterizations.
Conclusions
In conclusion, this study for the first time revealed the implications of TLS localization and maturation heterogeneity on the clinical outcomes and immunological status and responses of ccRCC, allowing the identification of immunophenotypes and the improvement of immunotherapeutic effectiveness for ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1027P - An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Presenter: Byoung Chul Cho
Session: Poster session 19
1028P - Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Presenter: Daphne Day
Session: Poster session 19
1029P - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Presenter: Anthony Olszanski
Session: Poster session 19
1030P - Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1032P - A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Presenter: Zhi Peng
Session: Poster session 19
1033P - First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Presenter: Aung Naing
Session: Poster session 19
1034P - Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Presenter: Alexander Starodub
Session: Poster session 19
1035P - Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Presenter: Ho Yeong Lim
Session: Poster session 19
1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Presenter: Junli Xue
Session: Poster session 19